Prednisone
- Generic Name
- Prednisone
- Brand Names
- Deltasone, Rayos, Winpred
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26O5
- CAS Number
- 53-03-2
- Unique Ingredient Identifier
- VB0R961HZT
- Background
A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.
Prednisone was granted FDA approval on 21 February 1955.
- Indication
Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.
- Associated Conditions
- Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis
- Associated Therapies
- Palliative Treatment
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Phase 3
Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Other: Laboratory Biomarker AnalysisDrug: MelphalanDrug: LenalidomideDrug: PrednisoneOther: Quality-of-Life AssessmentDrug: Thalidomide
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 306
- Registration Number
- NCT00602641
- Locations
- 🇺🇸
Illinois CancerCare-Peoria, Peoria, Illinois, United States
🇺🇸Methodist Medical Center of Illinois, Peoria, Illinois, United States
🇺🇸OSF Saint Francis Medical Center, Peoria, Illinois, United States
Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate
Phase 2
Withdrawn
- Conditions
- Stage II Prostate CancerAdenocarcinoma of the ProstateStage I Prostate CancerProstate Cancer
- Interventions
- First Posted Date
- 2008-01-23
- Last Posted Date
- 2016-12-08
- Lead Sponsor
- John P. Fruehauf
- Registration Number
- NCT00598858
Prednisone Withdrawal Versus Prednisone Maintenance After Kidney Transplant
Phase 4
Terminated
- Conditions
- Transplants and Implants
- Interventions
- First Posted Date
- 2008-01-17
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 18
- Registration Number
- NCT00596947
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Inflammatory, Functional and Image Composite Measure to Define Asthma Control
Phase 4
- Conditions
- Asthma
- First Posted Date
- 2008-01-17
- Last Posted Date
- 2008-01-17
- Lead Sponsor
- Federal University of São Paulo
- Target Recruit Count
- 70
- Registration Number
- NCT00597064
- Locations
- 🇧🇷
Rua Botucatu 740 3 ° and - Pneumologia, São Paulo, Sao Paulo, Brazil
Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2008-01-08
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- Northwell Health
- Target Recruit Count
- 95
- Registration Number
- NCT00588406
- Locations
- 🇺🇸
Nassau University Medical Center, East Meadow, New York, United States
🇺🇸Long Island Jewish Medical Center, Queens, New York, United States
🇺🇸Jacobi Medical Center, Bronx, New York, United States
A Safety Analysis of Oral Prednisone as a Pre-Treatment for Rituximab in Rheumatoid Arthritis.
- First Posted Date
- 2007-12-24
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- University of South Florida
- Target Recruit Count
- 50
- Registration Number
- NCT00580229
- Locations
- 🇺🇸
University of South Florida, Tampa, Florida, United States
🇺🇸Arthritis Research of Florida, Inc., Palm Harbor, Florida, United States
Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients
Phase 3
Completed
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2020-11-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 210
- Registration Number
- NCT00577993
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
Recruiting
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2007-12-18
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Gelb, Arthur F., M.D.
- Target Recruit Count
- 60
- Registration Number
- NCT00576069
- Locations
- 🇺🇸
Arthur F Gelb Medical Corporation, Lakewood, California, United States
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
Phase 2
Completed
- Conditions
- Lymphoma
- Interventions
- Drug: cyclophosphamideDrug: cyclosporineDrug: fludarabine phosphateDrug: gemcitabine hydrochlorideDrug: ifosfamideDrug: mechlorethamine hydrochlorideDrug: melphalanDrug: methotrexateDrug: mycophenolate mofetilDrug: prednisoneDrug: procarbazine hydrochlorideDrug: vincristine sulfateDrug: vinorelbine tartrateProcedure: allogeneic bone marrow transplantationProcedure: allogeneic hematopoietic stem cell transplantationProcedure: nonmyeloablative allogeneic hematopoietic stem cell transplantationProcedure: peripheral blood stem cell transplantationProcedure: umbilical cord blood transplantationRadiation: total-body irradiation
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT00574496
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Phase 3
Completed
- Conditions
- Acute Undifferentiated LeukemiaAcute Lymphoblastic LeukemiaChildhood T Acute Lymphoblastic Leukemia
- Interventions
- Drug: AsparaginaseProcedure: Biospecimen CollectionProcedure: Bone Marrow BiopsyDrug: CyclophosphamideDrug: CytarabineDrug: Daunorubicin HydrochlorideDrug: DexamethasoneProcedure: EchocardiographyDrug: EtoposideBiological: FilgrastimOther: Laboratory Biomarker AnalysisDrug: Leucovorin CalciumDrug: LestaurtinibDrug: MercaptopurineDrug: MethotrexateDrug: MethylprednisoloneProcedure: Multigated Acquisition ScanDrug: PegaspargaseOther: Pharmacological StudyDrug: PrednisoneDrug: Therapeutic HydrocortisoneDrug: Vincristine Sulfate
- First Posted Date
- 2007-11-12
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 218
- Registration Number
- NCT00557193
- Locations
- 🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇺🇸MedStar Georgetown University Hospital, Washington, District of Columbia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath